GlassScriptPhysician profile
Anna Rita Foraci
NPI 1477535466
$5,906.16
in general payments reported to CMS, 2019-2025
36 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $495 · 2021: $555 · 2022: $1,194 · 2023: $973 · 2024: $1,025 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,097.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,142.89 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $1,090.50 | 2021-2025 | |
| Novo Nordisk INC | $770.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $601.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $451.83 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $268.51 | 2020-2025 | |
| Dexcom, INC. | $173.73 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $134.58 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.91 | 2020-2025 | Jardiance, Tradjenta |
| Amgen INC. | $119.73 | 2019-2022 | |
| Amarin Pharma, INC. | $101.49 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $85.27 | 2019-2022 | |
| Allergan, INC. | $76.94 | 2019-2020 | |
| Abbott Laboratories | $75.25 | 2022-2023 | Freestyle Libre 3 |
| Boston Scientific Corporation | $68.65 | 2019-2025 | Wavewriter Alpha Prime 16 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $59.56 | 2019-2022 | |
| Esperion Therapeutics, INC. | $51.74 | 2020-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $50.90 | 2022-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $44.10 | 2019-2022 | |
| Hologic Sales and Service, LLC | $44.03 | 2023-2025 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $34.65 | 2020-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $33.12 | 2019-2021 | |
| Gilead Sciences, INC. | $29.14 | 2024 | |
| Ibsa Pharma INC. | $26.67 | 2022 | |
| Eisai INC. | $26.67 | 2024 | |
| Novartis Pharmaceuticals Corporation | $24.68 | 2019 | |
| Horizon Therapeutics Plc | $24.29 | 2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $22.04 | 2019 | |
| Si-Bone, INC. | $21.93 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $20.38 | 2023 | Evkeeza |
| Stryker Corporation | $19.06 | 2019 | |
| Sanofi Pasteur INC. | $17.62 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.16 | 2022 | |
| Halozyme INC | $17.03 | 2023 | |
| Idorsia Pharmaceuticals US INC | $14.46 | 2023 | Quviviq |
| Acerus Pharmaceuticals Corporation | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Foraci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.